Sputnik V to face stiff competition in India: GlobalData
Sputnik V to face stiff competition in India: GlobalData
20 April 2021 | News
Source credit: Shutterstock
With the Sputnik V vaccine’s recent approval, India now has three vaccines authorised for COVID-19 treatment. However, despite better efficacy over Serum Institute of India/ AstraZeneca’s Covishield and Bharat Biotech’s COVAXIN, Sputnik V will face stiff competition in India, says GlobalData.
Dr Reddy s Laboratories (DRL) will receive Sputnik V from the Russian Direct Investment Fund (RDIF) by mid-May 2021 and local production is expected to commence from July–September 2021 timeframe.
Sputnik V pricing will be key for gaining a solid foothold in India. Its price is expected to be slightly higher compared to Covishield and COVAXIN due to its higher efficacy.